Acute stroke therapy

The combined experience with IV rt-PA treatment beyond 3 hours, therefore, suggests reduced effectiveness compared to treatment within 3 hours. A pooled analysis of the ATLANTIS, ECASS, and NINDS rt-PA studies confirmed that the odds of a favorable 3-month outcome, defined as minimal or no poststroke disability on the BI, mRS, and NIHSS, decreased with increasing stroke onset to start of treatment time (OTT) (p = 0.005). The odds ratios for favorable outcome with rt-PA treatment were 2.8 (95% Cl 1.8. 5) for OTT 0-90 minutes, 1.6 (95% Cl 1.1-2.2) for 91-180 minutes, 1.4 (95% Cl 1.1-1.9) for 181-270 minutes, and 1.2 (95% Cl 0.9-1.5) for 271-360 minutes. This finding, that earlier treatment is associated with more therapeutic efficacy, supports the adage that in the delivery of acute stroke therapy time is brain. " The rate of sICH was not associated with OTT. ... [Pg.45]

NONTHROMBOLYTIC ACUTE STROKE THERAPIES 3-Month mRs by ALB dose-tier tPA cohofl... [Pg.106]

Eisher M, Albers GW, Donnan GA, Eurlan AJ, Grotta JC, Kidwell CS, Sacco RL, Wechsler LR. Enhancing the development and approval of acute stroke therapies stroke therapy academic industry roundtable. Stroke 2005 36 1808-1813. [Pg.114]

ACUTE STROKE THERAPY WITH OTHER ANTIPEATEEET AGENTS... [Pg.147]

A number of evidence-based guidelines exist to help choose appropriate acute stroke therapy. [Pg.155]

Fink JN, Kumar S, Horkan C, Linfante I, Selim MH, Caplan LR, Schlaug G (2002) The stroke patient who woke up clinical and radiological features, including diffusion and perfusion MRI. Stroke 33 988-993 Fisher M (1997) Characterizing the target of acute stroke therapy. Stroke 28 866-872... [Pg.38]

In summary, the main role of CT in acute stroke is to exclude hemorrhage. Owing to the limitations in visualization of ischemia, especially in the early stages, CT cannot be used to stratify participants reliably according to infarct location or size in trials of acute stroke therapy, although it is currently used to exclude major completed infarction prior to early thrombolysis. [Pg.148]

Karepov VC, Cur AY, Bova I et al. (2006). Stroke-in-evolution infarct-inherent mechanisms versus systemic causes. Cerebrovascular Diseases 21 42-46 Kent TA, Soukup VM, Fabian RH (2001). Heterogeneity affecting outcome from acute stroke therapy making reperftision worse. Stroke 32 2318-2327... [Pg.212]

LaRue LJ, Alter M, Traven ND et al. (1988). Acute stroke therapy trials problems in patient accrual. Stroke 19 950-954 Marshall M, Lockwood A, Bradley C et al. (2000). Unpublished rating scales a major source of bias in randomised controlled trials of treatments for schizophrenia British Journal of Psychiatry 176 249-252 Medical Research Council Working Party (1985). MRC trial of treatment of mild... [Pg.237]

Ki ams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA, ASTIN Study hivesdgators (2003) Acute Stroke Therapy by fiihi-bidon of Neutiophils (ASTIN) An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 34 2543—2548. [Pg.442]

ADAM a disintegrin and metaUoprotease ASTIN acute stroke therapy by inhibition of... [Pg.869]

M. Krams, K. R. Lees, W. Hacke, A. P. Grieve, J. M. Orgogozo, and G. M. Ford, Acute stroke therapy by inhibition of neutrophils (ASTIN) an adaptive dose-response study of UK279276 in acute ischemic stroke. Stroke 34 2543-2548 (2003). [Pg.826]

Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke therapy academic industry roundtable (stair) recommendations for extended window acute stroke therapy trials. Stroke. 2009 40 2594-2600... [Pg.20]

Donnan GA, Baron J, Ma H, Davis SM Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol 2009 8 pp. 261-269. [Pg.39]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...